24 results
PRE 14A
AXLA
Axcella Health Inc.
7 Aug 23
Preliminary proxy
4:15pm
to render audit or non-audit services unless the service is specifically approved in advance by our audit committee, or the engagement is entered
8-K
EX-99.1
AXLA
Axcella Health Inc.
13 Oct 22
Entry into a Material Definitive Agreement
8:15am
the net proceeds from the offering together with existing cash and cash equivalents to advance the Long COVID program, including regulatory engagement
8-K
AXLA
Axcella Health Inc.
13 Oct 22
Entry into a Material Definitive Agreement
8:15am
program, including regulatory engagement and preparation for further clinical development; advance and complete enrollment of our EMMPACT Phase 2b
424B5
re86s6bqr9 wkxpp85
13 Oct 22
Prospectus supplement for primary offering
7:55am
8-K
EX-99.2
j0n fe192
29 Sep 22
Regulation FD Disclosure
9:15am
8-K
EX-99.2
39b4s7y
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.1
yhq2tm
10 Jan 22
Other Events
8:00am
8-K
EX-99.1
d78x89ii
29 Jul 21
Axcella Reports Second Quarter Financial Results and Provides Business Update
7:58am
8-K
EX-99.1
qgne2l7ashuc
17 Mar 21
Axcella Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
7:44am
8-K
EX-99.1
8zxwopv bo
12 Nov 20
Axcella Reports Third Quarter 2020 Financial Results and Provides Business Update
7:47am
8-K
EX-99.1
1o0gmh99jozj5lj2p1
5 Aug 20
Axcella Reports Positive Top-Line Data from AXA1665-002 and Second Quarter Financial Results
8:22am
DEF 14A
u7ik310lnswz
3 Apr 20
Definitive proxy
4:15pm
8-K
EX-10.1
6jzf4 nubh2x9
25 Nov 19
Axcella Strengthens Executive Team with Key Addition and Promotion
8:11am